Sensei Biotherapeutics Inc (SNSE)

$31.02 -3.77 (-10.84%)
Market Cap 41.58M
Revenue (ttm) 0.00
Net Income (ttm) -30.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 66,400
Avg Vol 368,434
Day's Range N/A - N/A
Shares Out 1.34M
Stochastic %K 61%
Beta -0.10
Analysts Hold
Price Target $35.00

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 243 8000
Address:
1405 Research Boulevard, Suite 125, Rockville, United States
andycoolbeans
andycoolbeans Apr. 3 at 1:35 AM
$SNSE Sensei Biotherapeutics (SNSE): ~97% of float short (extremely high; small biotech with low float).
0 · Reply
RetireB4FortyX
RetireB4FortyX Apr. 1 at 7:11 PM
$SNSE SNSE Stock Analysis: Low Float Biotech Stock Analysis Here: https://shorturl.at/h9iAh Make sure to check out our new discord if you haven't already
0 · Reply
Few_erish
Few_erish Apr. 1 at 6:23 PM
$SNSE not sure yet, keeping it up
0 · Reply
RetireB4FortyX
RetireB4FortyX Apr. 1 at 4:38 PM
$SNSE From $22 up to $36. Still heavily shorted. Our new discord channel is now up and running
0 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Apr. 1 at 3:31 PM
$SNSE going to 50 soon i think
0 · Reply
MetricWhale
MetricWhale Apr. 1 at 10:14 AM
$SNSE One of my top Calls in 2026
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 1 at 2:03 AM
Wealthy Wednesday Watchlist Pt.6 $ABVE $IVF $IBG $QCLS $SNSE Let's Fly Team
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 1 at 1:21 AM
New Video out on the Bullish Analysis on $QCLS $ASTI $PGEN $SNSE $IVF and More https://www.youtube.com/watch?v=vckxxSleOtY
0 · Reply
burkerr07
burkerr07 Mar. 31 at 8:14 PM
$SNSE great day so far! Huge short interest here
0 · Reply
Few_erish
Few_erish Mar. 31 at 7:40 PM
$SNSE not dead yet
0 · Reply
Latest News on SNSE
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:30 AM EDT - 6 days ago

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026, 6:00 AM EDT - 19 days ago

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Feb 18, 2026, 8:00 AM EST - 6 weeks ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Jan 7, 2026, 8:00 AM EST - 3 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 7:30 AM EST - 5 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 30, 2025, 9:00 AM EDT - 5 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 23, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jul 30, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Jun 13, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Upcoming Conferences

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 23, 2024, 5:10 PM EDT - 2 years ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

Jun 1, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 20, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 18, 2023, 4:05 PM EDT - 3 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

andycoolbeans
andycoolbeans Apr. 3 at 1:35 AM
$SNSE Sensei Biotherapeutics (SNSE): ~97% of float short (extremely high; small biotech with low float).
0 · Reply
RetireB4FortyX
RetireB4FortyX Apr. 1 at 7:11 PM
$SNSE SNSE Stock Analysis: Low Float Biotech Stock Analysis Here: https://shorturl.at/h9iAh Make sure to check out our new discord if you haven't already
0 · Reply
Few_erish
Few_erish Apr. 1 at 6:23 PM
$SNSE not sure yet, keeping it up
0 · Reply
RetireB4FortyX
RetireB4FortyX Apr. 1 at 4:38 PM
$SNSE From $22 up to $36. Still heavily shorted. Our new discord channel is now up and running
0 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Apr. 1 at 3:31 PM
$SNSE going to 50 soon i think
0 · Reply
MetricWhale
MetricWhale Apr. 1 at 10:14 AM
$SNSE One of my top Calls in 2026
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 1 at 2:03 AM
Wealthy Wednesday Watchlist Pt.6 $ABVE $IVF $IBG $QCLS $SNSE Let's Fly Team
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 1 at 1:21 AM
New Video out on the Bullish Analysis on $QCLS $ASTI $PGEN $SNSE $IVF and More https://www.youtube.com/watch?v=vckxxSleOtY
0 · Reply
burkerr07
burkerr07 Mar. 31 at 8:14 PM
$SNSE great day so far! Huge short interest here
0 · Reply
Few_erish
Few_erish Mar. 31 at 7:40 PM
$SNSE not dead yet
0 · Reply
Rach7117
Rach7117 Mar. 31 at 6:48 PM
$SNSE huge short interest here
0 · Reply
RetireB4FortyX
RetireB4FortyX Mar. 31 at 4:17 PM
$SNSE
0 · Reply
RetireB4FortyX
RetireB4FortyX Mar. 31 at 3:57 PM
$SNSE Making a move here now. Heavily shorted
0 · Reply
RetireB4FortyX
RetireB4FortyX Mar. 31 at 2:15 PM
$SNSE The spread here is insane
0 · Reply
burkerr07
burkerr07 Mar. 31 at 2:52 AM
$SNSE
0 · Reply
RetireB4FortyX
RetireB4FortyX Mar. 31 at 2:30 AM
$SNSE $NGNE $KALV $XWEL Most Shorted Stocks This Week of 3/30/2026 Full Stock Analysis Here: https://shorturl.at/33ujH Make sure to follow and sign up for our free newsletter. We will be rolling out our new discord this week
0 · Reply
stinkystock
stinkystock Mar. 29 at 10:41 PM
$SNSE Another run Coming---Put Your Panties On!
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 10:30 PM
$SNSE over 50 soon i think
0 · Reply
planenuts444
planenuts444 Mar. 19 at 11:36 PM
$SNSE Sensei Biotherapeutics ( SNSE) is estimated to release its Q4 2025 earnings on Friday, March 27, 2026. How does everyone feel about this upcoming event?
0 · Reply
fasteddiecakes
fasteddiecakes Mar. 18 at 1:30 PM
$UCAR lots of scred shorts here today. LOL $SNSE $EONR $BATL
0 · Reply
DARKP00L
DARKP00L Mar. 17 at 10:22 AM
$SNSE 06:05 on Mar. 17 2026 Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule #tradeideas
0 · Reply
luklyz
luklyz Mar. 16 at 7:19 PM
$SNSE they aquire Faeth Therapeutics and it is difficult to find any information about both companies. Here is a link to Faeth ongoing Phase 2 for the use sapaniserib https://clinicaltrials.gov/study/NCT06463028?spons=Faeth%20Therapeutics&rank=1 Big problem is that this study will not be done till 2029. The study was started in 2024. Most likely the preliminary data will be released sometime end of 2026 or early 2027.
0 · Reply